Company Overview and News


Add EGLT
to your dashboard

Headline News

Biotech Forum Daily Digest: What Heron's FDA Approval Means

2017-11-17 seekingalpha
The small biotech sector staged an almost two percent 'relief rally' Thursday after falling some 10% over the past month. (73-3)

Egalet Ltd. 2017 Q3 - Results - Earnings Call Slides

2017-11-10 seekingalpha
The following slide deck was published by Egalet Ltd. in conjunction with their 2017 Q3 earnings call. (36-0)

Egalet's (EGLT) CEO Bob Radie on Q3 2017 Results - Earnings Call Transcript

2017-11-09 seekingalpha
Good morning, ladies and gentlemen and welcome to the Egalet 2017 Third Quarter Earnings Conference Call. Now all participants are in listen-only mode. [Operator Instructions] After managements' remarks, there will be an opportunity to ask questions. [Operator Instructions] As a reminder, today's conference call is being recorded. (36-2)

Egalet Corporation to Host Earnings Call

2017-11-08 accesswire
(36-0)

Your Daily Pharma Scoop: Synergy Must Buy, RedHill Positive Data, CTMX-AMGN Collaboration

2017-10-04 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (866-17)

Former GlaxoSmithKline CEO, R&D Head Secure New Gigs at Biotech VC Firms

2017-09-19 biospace
LONDON & GENEVA & JERSEY--(BUSINESS WIRE)--Medicxi, the leading European life sciences investment firm, today announces that Dr Moncef Slaoui, alongside his other commitments, has joined its team as Partner. Dr Slaoui was formerly GSK’s Chairman of Pharmaceutical R&D and of its vaccines division. (110-5)

National Lacrosse League and Egalet Corporation Announce Educational Partnership Around A Non-Narcotic Pain Option and Responsible Pain Management

2017-09-18 prnewswire
PHILADELPHIA and WAYNE, Pa., Sept. 18, 2017 /PRNewswire/ -- The National Lacrosse League (NLL), the largest men's professional indoor lacrosse league in North America, and Egalet Corporation (Nasdaq: EGLT), a specialty pharmaceutical company focused on developing innovative treatments for pain and other conditions, today announced a partnership focused on physician education around responsible pain management. (36-0)

Stocks Under Scanner in the Biotech Space -- Curis, Egalet, and Esperion Therapeutics

2017-09-13 prnewswire
If you want a Stock Review on CRIS, EGLT, or ESPR then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. On Tuesday, September 12, 2017, the NASDAQ Composite ended the trading session at 6,454.28, up 0.34%; the Dow Jones Industrial Average edged 0.28% higher to finish at 22,118.86; and the S&P 500 closed at 2,496.48, slightly advancing 0.34%. Gains were broad based as seven out of nine sectors ended the day in positive. (0-1)

Acura Pharmaceuticals' (ACUR) CEO Bob Jones on Q2 2017 Results - Earnings Call Transcript

2017-08-15 seekingalpha
Good day and welcome to the Acura Pharmaceuticals Second Quarter 2017 Results Conference Call. Today's conference is being recorded. (0-1)

Egalet Cuts Workforce By 40% in Expense Reduction Plan

2017-08-10 biospace
WAYNE, Penn., Aug. 9, 2017 /PRNewswire/ -- Egalet Corporation (Nasdaq: EGLT) (Egalet), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, today announced financial results for the second quarter ended June 30, 2017 and an expense reduction plan to support Egalet's path toward profitability. (0-1)

Egalet's (EGLT) CEO Bob Radie on Q2 2017 Results - Earnings Call Transcript

2017-08-09 seekingalpha
Good afternoon, ladies and gentlemen and welcome to the Egalet 2017 Second Quarter Earnings Conference Call. At this time, all participants are in listen-only mode. [Operator Instructions]. After managements' remarks, there will be an opportunity to ask questions. [Operator Instructions]. As a reminder, today's conference call is being recorded.

Egalet's Guardian Technology Begins Fight Against Opioid Abuse Epidemic

2017-08-01 seekingalpha
Egalet Corporation’s one-dimensional pipeline and labeling woes have sent stock price plummeting ~75% in the last year.

Stock Research Report

Egalet Corporation is a fully integrated specialty pharmaceutical company developing, manufacturing and commercializing innovative treatments for pain and other conditions. Given the need for acute and chronic pain products and the issue of prescription abuse, the company focused on bringing non-narcotic and abuse-deterrent (“AD”) opioid formulations to patients and physicians. Egalet is currently marketing ARYMO® ER (morphine sulfate) extended-release (“ER”) tablets, for oral use CII (“ARYMO ER”), SPRIX® (ketorolac tromethamine) Nasal Spray (“SPRIX Nasal Spray”), and OXAYDO® (oxycodone HCI, USP) tablets for oral use only—CII (“OXAYDO”).

ARYMO ER, an ER morphine product formulated with abuse-deterrent properties and approved for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate, is its first product developed using its proprietary Guardian™ Technology. Egalet acquired, and...

Click for full article
CUSIP: 28226B104